Company Description

Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations.